Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BioNTech SE - ADR (BNTX) vs VanEck Vietnam ETF (VNM) Price & Performance

BioNTech SE - ADRTrade
VanEck Vietnam ETFTrade

Price performance (Past 24H)

Key statistics

BioNTech SE - ADR vs VanEck Vietnam ETF — how do they compare? BioNTech SE - ADR trades at $92.94 (market cap $23.31B), while VanEck Vietnam ETF trades at $17.8. The key difference: VanEck Vietnam ETF is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.

BNTXVNM
Market Cap
$23.31B
Sector
HealthSector/Thematic
52-Week High
$119.34$19.80
52-Week Low
$83.89$16.34
Enterprise Value
$6.60B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BioNTech SE - ADR

BioNTech (BNTX) trades at $92.72, down 0.09% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 revenue of €106 million, missing expectations due to weak COVID-19 vaccine demand, and lowered its 2026 sales outlook. Despite negative profitability metrics (net income margin -63.64%, ROE -9.3%), the balance sheet remains strong with $16.78 billion in cash. Analyst consensus is strongly bullish with 87.5% buy ratings and a $121 price target.

The outlook for BNTX hinges on its oncology pipeline development amid declining COVID revenue. Investment opportunity exists in the discounted valuation relative to cash reserves and potential pipeline catalysts. Key risks include execution on pipeline transitions, competitive pressure, and ongoing vaccine demand volatility. The stock trades near cash value, implying the market assigns minimal value to its advanced clinical programs.

VanEck Vietnam ETF

VNM stock trades at $17.80, up 0.91% with a bullish technical signal despite mixed indicators. The stock faces resistance at $18 with support at $17. Recent news highlights Vietnam's economic challenges including power grid strain and FTSE Russell's EM reclassification affecting foreign investment flows.

The stock shows technical strength but faces fundamental data gaps and regional economic headwinds. Investment opportunity exists if Vietnam's market reclassification attracts foreign capital, though power infrastructure risks and broader Asian equity outflows present near-term challenges.

Returns comparison

Trailing returns across standard periods

About BioNTech SE - ADR

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.

Read more on BNTX

About VanEck Vietnam ETF

VNM is the first and largest U.S.-listed ETF providing targeted exposure to the Vietnamese equity market. It tracks the MarketVector™ Vietnam Local Index, which includes publicly traded companies that are locally incorporated in Vietnam. It serves as a liquid, transparent vehicle for investors looking to participate in Vietnam's transition into a global manufacturing hub and its long-term potential for emerging market reclassification.

Read more on VNM